Categories AlphaGraphs, Earnings, LATEST, Retail

Darden beats Q1 sales and earnings expectations; raises outlook

Darden Restaurants Inc. (DRI) topped analysts’ expectations on sales and earnings for the first quarter of 2019. Shares rose over 4% during premarket trade following the results announcement.

The restaurant chain reported a 6.5% increase in total sales to $2.06 billion compared to the same period last year. The sales increase included a 3.2% growth from the addition of 52 net new restaurants. Blended same-restaurant sales rose 3.3%.

Net income grew to $166.2 million or $1.32 per share from $119 million or $0.93 per share last year. Adjusted diluted EPS from continuing operations was $1.34.

Darden Restaurants first quarter 2019 earnings
Darden Restaurants Q1 2019 Earnings Infographic

Darden posted net sales increases across all its segments during the quarter. Same-restaurant sales increased across most of its brands except for Cheddar’s Scratch Kitchen and Seasons 52. The highest growth was in Olive Garden where same-restaurant sales rose 5.3%.

Last month, the company was affected by a cybersecurity incident at several of its Cheddar’s Scratch Kitchen restaurants in which payment card information is said to have been compromised. Darden took immediate steps to rectify the situation and is cooperating with the investigation into the incident.

Based on its year-to-date results and expectations for the remainder of the year, Darden increased its outlook for the full year of 2019. The company now expects total sales growth of 5% to 5.5% versus the previous range of 4% to 5%.

Same-restaurant sales are expected to grow 2% to 2.5% versus the previous expectation of 1% to 2%. Diluted EPS from continuing operations is expected to be $5.52 to $5.65 versus the prior range of $5.40 to $5.56.

Darden’s board of directors declared a quarterly cash dividend of $0.75 per common share, payable November 1 to shareholders of record on October 10.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top